TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 DKK)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
4
|
1,333 | |
| Financial expenses |
10
|
5 | |
| Earnings before taxes |
-51
|
1,165 | |
| EBITDA |
-105
|
1,154 | |
| Total assets |
2,061
|
2,673 | |
| Current assets |
1,340
|
2,031 | |
| Current liabilities |
68
|
420 | |
| Equity capital |
1,835
|
2,084 | |
| - share capital |
32
|
34 | |
| Employees (average) |
1
|
1
|
2 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
89.0%
|
78.0% | |
| Turnover per employee |
4
|
666 | |
| Profit as a percentage of turnover |
-1275.0%
|
87.4% | |
| Return on assets (ROA) |
-2.0%
|
43.8% | |
| Current ratio |
1970.6%
|
483.6% | |
| Return on equity (ROE) |
-2.8%
|
55.9% | |
| Change turnover |
-1,285
|
-47 | |
| Change turnover % |
-100%
|
-100%
|
-3% |
| Chg. No. of employees |
0
|
-1
|
1 |
| Chg. No. of employees % |
0%
|
-50%
|
100% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.